PHARMACOLOGICAL ACTIVATION OF THE TRKB RECEPTOR AND ITS EFFECT OF BODY WEIGHT

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本项目的目的是获得激活trkB受体的重组人蛋白的初步数据，该重组人蛋白通过静脉注射给患有胰岛素抵抗、空腹血糖受损（前驱糖尿病）、高血糖和血红蛋白A1c （HbA1c）水平升高的肥胖雌性狒狒，对体重、体成分、空腹血糖水平和其他与碳水化合物、脂质和脂肪组织代谢相关的生化参数的影响。被研究的动物被分为两组；治疗组（n = 5）和对照组（n = 5）各1个。在基线时，通过DEXA、形态计量学（体重、腰围）、葡萄糖耐量评估所有动物的身体组成，并进行基线血液采集以进行代谢谱分析。治疗组每日静脉给药（2mg/kg/天），疗程6周。在研究过程中，再次评估所有动物的身体组成、形态计量学、葡萄糖耐量，并在第3周和第6周结束时采集血液样本。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The aim of this project was to obtain preliminary data on the efficacy of a recombinant human protein that activates the trkB receptor intravenously administer to obese female baboons with insulin resistance, impaired fasting glucose (prediabetes), hyperglycemia and elevated hemoglobin A1c (HbA1c) levels, on weight, body composition, fasting blood glucose levels and other biochemical parameters related to carbohydrate, lipid and fat tissue metabolism. The animals studied were divided into two groups; one treatment (n = 5) and one control group (n = 5). At baseline all animals were assessed for body composition by DEXA, morphometrics (weight, waist circumference), glucose tolerance and had a baseline blood collection for metabolic profiling. The treatment group received a daily IV dose of the test compound (2mg/kg/day) for a period of 6 weeks. During the course of the study all animals were again assessed for body composition, morphometrics, glucose tolerance along with the collection of a blood sample at the end of weeks 3, and 6.